Ferran Cardoso Rodriguez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ferran Cardoso Rodriguez has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Christopher J. Tape
Cell Communication Lab, Department of Oncology, University College London Cancer Institute, London, UK
26 shared publications - Jahangir Sufi
Advanced Cytometry Platform, Guy's and St Thomas' NHS Foundation Trust, London, UK
25 shared publications - Xiao Qin
Cell Communication Lab, Department of Oncology, University College London Cancer Institute
25 shared publications - Maria Ramos Zapatero
Cell Communication Laboratory, Department of Oncology, University College London Cancer Institute, London, United Kingdom
24 shared publications - Petra Vlckova
Cell Communication Laboratory, Department of Oncology, University College London Cancer Institute, 72 Huntley Street, London, UK
24 shared publications - Callum Baird Nattress
Cell Communication Laboratory, Department of Oncology, University College London Cancer Institute, London, United Kingdom
23 shared publications
Latest Publications
- Open Access
A Digital Environment for Multi-modal Relational Management, Representation, and Analysis of Cancer Clinical Studies
Biologically rich clinical trials generate heterogeneous datasets whose relationships and clinical context must be preserved. Here we present the POETIC-AI environment, a trial-centric digital environment for integrating, analysing, and exploring multimodal data from POETIC, a randomised phase III trial of peri-operative aromatase inhibition in hormone receptor-positive breast cancer ( NCT02338310 ). We implemented a graph-based ontology linking patients, treatments, sampling timepoints, specimens, assays, images, spatial regions, and derived measurements; and designed code-based and graphical analytical workflows. Using proliferation as a test case, we reproduced POETIC’s established reduction in Ki67% and examined variation underlying sample-level measurements. In response-enriched cohorts, mean Ki67% decreased while relative variation among pathologist-assessed fields increased (paired Wilcoxon, P < 0.0001). Pathologist-assessed Ki67% correlated strongly with an 18-gene transcriptomic proliferation signature ( r = 0.834), and both decreased significantly during treatment (P < 0.0001). An annotation-free pixel-wise Ki67 H-score showed weaker correlations and a similar but non-significant reduction ( r = 0.327-0.472; P = 0.15), highlighting differences between tumour-focused and whole-section image quantification. Digital pathology and spatial molecular measurements remained linked to their source images and annotated tissue regions, enabling exploration within their morphological and spatial context using bespoke interactive applications. POETIC-AI demonstrates how the structure, provenance, and tissue context of evolving multimodal clinical-trial data can be preserved within a connected research environment, supporting reproducible analyses and the laying the groundwork for future development of biologically interpretable computational biomarkers.
Open AccessA Digital Environment for Multi-modal Relational Management, Representation, and Analysis of Cancer Clinical Studies
Biologically rich clinical trials generate heterogeneous datasets whose relationships and clinical context must be preserved. Here we present the POETIC-AI environment, a trial-centric digital environment for integrating, analysing, and exploring multimodal data from POETIC, a randomised phase III trial of peri-operative aromatase inhibition in hormone receptor-positive breast cancer ( NCT02338310 ). We implemented a graph-based ontology linking patients, treatments, sampling timepoints, specimens, assays, images, spatial regions, and derived measurements; and designed code-based and graphical analytical workflows. Using proliferation as a test case, we reproduced POETIC’s established reduction in Ki67% and examined variation underlying sample-level measurements. In response-enriched cohorts, mean Ki67% decreased while relative variation among pathologist-assessed fields increased (paired Wilcoxon, P < 0.0001). Pathologist-assessed Ki67% correlated strongly with an 18-gene transcriptomic proliferation signature ( r = 0.834), and both decreased significantly during treatment (P < 0.0001). An annotation-free pixel-wise Ki67 H-score showed weaker correlations and a similar but non-significant reduction ( r = 0.327-0.472; P = 0.15), highlighting differences between tumour-focused and whole-section image quantification. Digital pathology and spatial molecular measurements remained linked to their source images and annotated tissue regions, enabling exploration within their morphological and spatial context using bespoke interactive applications. POETIC-AI demonstrates how the structure, provenance, and tissue context of evolving multimodal clinical-trial data can be preserved within a connected research environment, supporting reproducible analyses and the laying the groundwork for future development of biologically interpretable computational biomarkers.
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation
Single-cell phenoscaping of γδ T-cell anti-PDO cytotoxicity. A, Experimental design and PDO27 B7-H3 expression measured by flow cytometry. B, γδ T-cell EMD PHATE at phenoscape (middle) and single-cell (insets) resolution. ×180 γδ T-cell–PDO cultures. EMD scores were calculated relative to unmodified-γδ monoculture controls to capture changes during stIL15 transduction and γδ coculture with PDO. C, γδ T PHATE annotated by PDO apoptosis. D, Therapeutic apoptosis via AIC or ADCC per γδ T-cell donor. Mean ± SD of triplicate samples. Two-way ANOVA with Sidak multiple comparisons test. The gray bar compares AIC; the orange bar compares cytotoxicity from AIC + B7-H3 mAb. E, ADCC killing in parental and B7-H3 CRISPR knockout PDO 27 demonstrate antigen specificity of ADCC killing. Unpaired t test (apoptosis values). Mean ± SD of quintuplet samples. F,x̄EMD of γδ T cells in monoculture or coculture with PDO27. Mean of six replicate samples per donor. The reference for x̄EMD scores for all conditions, including monoculture conditions, was calculated relative to monoculture controls. G, γδ T-cell S-phase ± PDOs. Six replicates per donor, with overall mean across all donors plotted. Two-way ANOVA with Tukey multiple comparisons test. H, EMD heatmap of stIL15-γδ T-cell PTM signaling and immunophenotyping markers ± B7-H3 mAb compared with monoculture controls for each stIL15-γδ T-cell donor. EMD scores were calculated relative to monoculture controls for each donor and treatment. ns, not significant; ***, P < 0.001; ****, P < 0.0001.
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation
Single-cell phenoscaping of γδ T-cell anti-PDO cytotoxicity. A, Experimental design and PDO27 B7-H3 expression measured by flow cytometry. B, γδ T-cell EMD PHATE at phenoscape (middle) and single-cell (insets) resolution. ×180 γδ T-cell–PDO cultures. EMD scores were calculated relative to unmodified-γδ monoculture controls to capture changes during stIL15 transduction and γδ coculture with PDO. C, γδ T PHATE annotated by PDO apoptosis. D, Therapeutic apoptosis via AIC or ADCC per γδ T-cell donor. Mean ± SD of triplicate samples. Two-way ANOVA with Sidak multiple comparisons test. The gray bar compares AIC; the orange bar compares cytotoxicity from AIC + B7-H3 mAb. E, ADCC killing in parental and B7-H3 CRISPR knockout PDO 27 demonstrate antigen specificity of ADCC killing. Unpaired t test (apoptosis values). Mean ± SD of quintuplet samples. F,x̄EMD of γδ T cells in monoculture or coculture with PDO27. Mean of six replicate samples per donor. The reference for x̄EMD scores for all conditions, including monoculture conditions, was calculated relative to monoculture controls. G, γδ T-cell S-phase ± PDOs. Six replicates per donor, with overall mean across all donors plotted. Two-way ANOVA with Tukey multiple comparisons test. H, EMD heatmap of stIL15-γδ T-cell PTM signaling and immunophenotyping markers ± B7-H3 mAb compared with monoculture controls for each stIL15-γδ T-cell donor. EMD scores were calculated relative to monoculture controls for each donor and treatment. ns, not significant; ***, P < 0.001; ****, P < 0.0001.
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 4 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation
Regulation of γδ T cells correlates with anti-PDO cytotoxicity. A, Single-cell PHATE of x10 PDOs + stIL15-γδ T cells ± B7-H3 mAb. B, PDO apoptosis via AIC or ADCC per γδ T donor across x10 PDOs. Two-way ANOVA with Sidak multiple comparisons test. Mean ± SD of triplicate samples. C, Correlation of γδ x̄EMD with anti-PDO cytotoxicity during AIC, colored by γδ granzyme B. τ denotes the Kendall rank correlation coefficient. D, Correlation of γδ x̄EMD with anti-PDO cytotoxicity + B7-H3 mAb, colored by γδ granzyme B. τ denotes the Kendall rank correlation coefficient. E, stIL15-γδ PTM signaling with PDOs ± B7-H3 mAb. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation
Regulation of γδ T cells correlates with anti-PDO cytotoxicity. A, Single-cell PHATE of x10 PDOs + stIL15-γδ T cells ± B7-H3 mAb. B, PDO apoptosis via AIC or ADCC per γδ T donor across x10 PDOs. Two-way ANOVA with Sidak multiple comparisons test. Mean ± SD of triplicate samples. C, Correlation of γδ x̄EMD with anti-PDO cytotoxicity during AIC, colored by γδ granzyme B. τ denotes the Kendall rank correlation coefficient. D, Correlation of γδ x̄EMD with anti-PDO cytotoxicity + B7-H3 mAb, colored by γδ granzyme B. τ denotes the Kendall rank correlation coefficient. E, stIL15-γδ PTM signaling with PDOs ± B7-H3 mAb. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 5 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation
B7-H3 mAb facilitates Fc receptor–dependant ADCC by stIL15-γδ T cells. A, Therapeutic apoptosis by stIL15-γδ T cells ± mAb ± mAb (Fc null), against colorectal cancer PDO 141. Two-way ANOVA with Dunnett multiple comparisons test. Mean ± SD of triplicate samples. B, Correlation between therapeutic apoptosis and B7-H3 epitope availability. The same clone of B7-H3 mAb was conjugated into the CyTOF staining panel to calculate the relative availability of B7-H3 epitope. C, EMD scores of stIL15-γδ T-cell granzyme B expression calculated relative to untreated coculture controls. One-way ANOVA with Sidak multiple comparisons test. Mean ± SD of triplicate samples. D, Decrease in stIL15-γδ T-cell % DNAM-1 expression relative to monoculture controls for each treatment. One-way ANOVA with Sidak multiple comparisons test. Mean ± SD of triplicate samples. *, P < 0.05; ***, P < 0.001; ****, P < 0.0001; ns, not significant.
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation
B7-H3 mAb facilitates Fc receptor–dependant ADCC by stIL15-γδ T cells. A, Therapeutic apoptosis by stIL15-γδ T cells ± mAb ± mAb (Fc null), against colorectal cancer PDO 141. Two-way ANOVA with Dunnett multiple comparisons test. Mean ± SD of triplicate samples. B, Correlation between therapeutic apoptosis and B7-H3 epitope availability. The same clone of B7-H3 mAb was conjugated into the CyTOF staining panel to calculate the relative availability of B7-H3 epitope. C, EMD scores of stIL15-γδ T-cell granzyme B expression calculated relative to untreated coculture controls. One-way ANOVA with Sidak multiple comparisons test. Mean ± SD of triplicate samples. D, Decrease in stIL15-γδ T-cell % DNAM-1 expression relative to monoculture controls for each treatment. One-way ANOVA with Sidak multiple comparisons test. Mean ± SD of triplicate samples. *, P < 0.05; ***, P < 0.001; ****, P < 0.0001; ns, not significant.
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 7 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation
Multimodal γδ T-cell cytotoxicity overcomes cellular therapy immunomodulation. γδ T-cell signaling networks following stIL15 transduction, coculture with PDO, and addition of B7-H3 mAb. Nodes are colored according to γδ EMD scores computed from >4 million cells across 576 conditions. Bottom, γδ cell-state histograms. Each cell-state phase is presented as the mean ± SD (n = 129–138). ITAM, immunoreceptor tyrosine-based activation motif.
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 7 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation
Multimodal γδ T-cell cytotoxicity overcomes cellular therapy immunomodulation. γδ T-cell signaling networks following stIL15 transduction, coculture with PDO, and addition of B7-H3 mAb. Nodes are colored according to γδ EMD scores computed from >4 million cells across 576 conditions. Bottom, γδ cell-state histograms. Each cell-state phase is presented as the mean ± SD (n = 129–138). ITAM, immunoreceptor tyrosine-based activation motif.
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation
Regulation of stIL15-γδs signalling and immunophenotype by CRC PDOs with or without anti-B7-H3 mAb
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation
Regulation of stIL15-γδs signalling and immunophenotype by CRC PDOs with or without anti-B7-H3 mAb
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation
Phenotype of stIL15-γδ T cells when co-cultured with CRC PDO27
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation
Phenotype of stIL15-γδ T cells when co-cultured with CRC PDO27
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation
Relationship between stIL15-γδ cytotoxicity and γδ T cell and PDO phenotypes
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation
Relationship between stIL15-γδ cytotoxicity and γδ T cell and PDO phenotypes
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation
Table S1 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation
Table S1 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation
StIL15-γδs phenotype regulation by CRC PDOs with or without anti-B7-H3 mAb
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation
StIL15-γδs phenotype regulation by CRC PDOs with or without anti-B7-H3 mAb